Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No Long-Term Benefit to Sentinel Lymph Node Biopsy in Most DCIS Patients

Publish date:: November 11, 2019

Key clinical point: Sentinel lymph node biopsy (SLNB) is not warranted in women with older patients with ductal carcinoma in situ (DCIS) amenable to breast conservation.

Major finding: With a median follow-up of 5.8 years, there were no significant differences in rates of recurrence, ipsilateral breast cancer, or breast cancer-specific mortality for SLNB versus no SLNB.

Study details: Retrospective study including 12,776 women aged 67-94 years who received a diagnosis of DCIS between 2001 and 2013 and underwent breast-conserving surgery.

Disclosures: The research was funded by an award from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Wang reported no disclosures, while co-authors provided disclosures related to Genentech, Eisai, Pfizer, Jonhson & Johnson, and 21st Century Oncology.

Citation:

Hung P et al. JNCI Cancer Spectr. 2019 Aug 7;3(4):pkz052. doi. 10.1093/jncics/pkz052. https://academic.oup.com/jncics/article/3/4/pkz052/5544720

This Week's Must Reads

Claims data improves cancer registry information on treatment,

Benefits and drawbacks found for risk-based lung cancer screening tools,

Patient-reported outcomes support first-line pembrolizumab for NSCLC,

Bilateral mastectomy reduces second breast cancer risk, but not deaths,

Study Links DLBCL, MZL in Sjogren’s Syndrome,

Must Reads in Breast Cancer

Bilateral mastectomy reduces second breast cancer risk, but not deaths,

Survival gains in HR+/HER2– MBC trials yet to be seen in real world,

Single-fraction radiation just misses mark for spinal compression relief,

Study Detects Lower CV Risk in Breast Cancer Survivors,

No Long-Term Benefit to Sentinel Lymph Node Biopsy in Most DCIS Patients,